Similar Search Results

The value of medical and pharmaceutical interventions for reducing obesity

Michaud, Pierre-Carl; Goldman, Dana P.; Lakdawalla, Darius - In: Journal of health economics 31 (2012) 4, pp. 630-643

Persistent link: https://www.econbiz.de/10010219980

Want more value from prescription drugs? : we need to let prices rise and fall

Goldman, Dana P.; Leive, Adam; Lakdawalla, Darius - In: The Economists' voice 10 (2013) 1, pp. 39-43

Persistent link: https://www.econbiz.de/10010228845

The economics of alternative payment models for pharmaceuticals

Hlávka, Jakub P.; Yu, Jeffrey C.; Goldman, Dana P.; … - In: The European journal of health economics 22 (2021) 4, pp. 559-569

Persistent link: https://www.econbiz.de/10012586512

Are biopharmaceutical budget caps good public policy?

Goldman, Dana P.; Lakdawalla, Darius; Baumgardner, James R. - In: The Economists' voice 13 (2016) 1, pp. 27-42

Persistent link: https://www.econbiz.de/10011585711

Chapter Thirteen. Intellectual Property, Information Technology, Biomedical Research, and Marketing of Patented Products

Goldman, Dana; Lakdawalla, Darius - In: Handbook of health economics : volume 2, (pp. 825-872). 2011

Intellectual property rights are viewed as essential to medical innovation, but very often involve social costs due to patent monopolies and other inefficiencies. We review the positive theory of innovation in health care, as it relates to the determination of innovation demand and supply. The...

Persistent link: https://www.econbiz.de/10014025575